InvestorsObserver is giving Ovid Therapeutics Inc (OVID) an Analyst Rating Rank of 29, meaning OVID is ranked higher by analysts than 29% of stocks. The average price target for OVID is $5 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating OVID a Buy today. Find out what this means to you and get the rest of the rankings on OVID!
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions **before** a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Ovid Therapeutics Inc Stock Today?
Ovid Therapeutics Inc (OVID) stock has fallen -5.54% while the S&P 500 has gained 1.39% as of 1:50 PM on Tuesday, Oct 5. OVID has fallen -$0.19 from the previous closing price of $3.43 on volume of 536,823 shares. Over the past year the S&P 500 has gained 27.92% while OVID has fallen -46.62%. OVID earned $1.68 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.93.
Click Here to get the full Stock Report for Ovid Therapeutics Inc stock.